论文部分内容阅读
目的:观察丹红注射液联合依帕司他治疗糖尿病视物神经病变疗效观察。方法:将符合1998年WHO标准诊断为2型糖尿病的46例患者随机分为治疗组和对照组。在常规治疗基础上,治疗组丹红注射液40mL/d加入250mL生理盐水中静脉滴注,同时予依帕司他50mg,1日3次,口服。而对照组仅用依帕司他50mg,1日3次,口服。临床观察2周,2周后观察其临床疗效及测定运动神经传导速度(MNCV),感觉神经传导速度(SNCV)。结果:治疗组患者临床总有效率92.8%,对照组总有效率68.0%,两组比较差异有统计学意义。治疗组治疗前后MNCV、SNCN指标比较,均极具有显著性统计学意义(P<0.01)。治疗组与对照组治疗后比较亦有统计学意义(P<0.05)。两组均无严重不良反应。结论:丹红注射液与依帕司他联合应用较后者单独应用更能提高糖尿病视物神经病变(DPN)治疗效果。
Objective: To observe the curative effect of Danhong injection combined with epalrestat on diabetic optic neuropathy. Methods: Forty-six patients diagnosed with type 2 diabetes who met WHO criteria in 1998 were randomly divided into treatment group and control group. On the basis of conventional treatment, the treatment group Danhong injection 40mL / d by adding 250mL saline intravenous infusion, while taking epalrestat 50mg, 1 3 times, orally. The control group only with epalrestat 50mg, 1 3 times, orally. The clinical effects were observed after 2 weeks and 2 weeks. The motor nerve conduction velocity (MNCV) and sensory nerve conduction velocity (SNCV) were measured. Results: The total clinical effective rate was 92.8% in the treatment group and 68.0% in the control group. The difference between the two groups was statistically significant. Before and after treatment, the MNCV and SNCN indexes of the treatment group were statistically significant (P <0.01). The treatment group and the control group after treatment were also statistically significant (P <0.05). No serious adverse reactions in both groups. Conclusion: The combination of Danhong injection and epalrestat can improve the therapeutic effect of diabetic optic neuropathy (DPN) more than the latter alone.